#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
Combining GLP-1 drugs and tesamorelin
No trial has tested combining retatrutide, tirzepatide and tesamorelin, and here is why doing so without clinical supervision is a real risk.
What GLP-1 labels say is worth tracking
The semaglutide and tirzepatide labels name specific things to monitor on a GLP-1, and the list is not the one a weight graph suggests.
Compounders hold on in the GLP-1 market
A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.
NVAC charter, GLP-1 telehealth: July 2026
NVAC gets a new charter on 7 July 2026, LifeMD faces GLP-1 telehealth allegations, and Medicare proposes 19% more pay for tobacco counselling.
LifeMD GLP-1 safety claims and Iowa's PBM
Former LifeMD employees allege GLP-1 prescriptions were rushed. An Iowa audit found a PBM may have overcharged Medicaid by over $100 million.
The obesity drug pipeline in 2026
A 2026 JCEM review maps next-generation obesity drugs, from approved dual agonists to triple agonists like retatrutide still in Phase 3.
Hengrui HRS-7535 oral GLP-1: Phase 3 data
Hengrui and Kailera reported Phase 3 results for HRS-7535, an oral GLP-1 drug, in July 2026. Here is what the peer-reviewed Phase 2 data shows.
GLP-1 drugs and US military adherence
A Military Health System study of 10,649 service members found tirzepatide led on adherence and persistence. Male members discontinued more often than females.
GLP-1 Drugs and Menstrual Changes
A 2026 FAERS study found semaglutide and tirzepatide linked to menstrual adverse events in females aged 12-55, adding a new dimension to GLP-1 counseling.
GLP-1 telehealth prescribing oversight
A Yale JAMA secret-shopper study flagged GLP-1 telehealth sites for thin clinical oversight. Here is what peer-reviewed evidence shows about platform quality.
Incretin drugs for T2D: 2026 NMA results
A 2026 network meta-analysis of 102 trials and 98,693 T2D patients ranked tirzepatide first for glycaemic control and retatrutide first for weight loss.
How semaglutide works: the GLP-1 receptor
Semaglutide binds the GLP-1 receptor in the pancreas, brain, and gut. Here is what happens at each site.